Clinical Research And Technology Development

Exhibit 99


FOR IMMEDIATE RELEASE


PHOTOGEN APPOINTS DAVID D. SHAW, PH.D. VICE PRESIDENT,
CLINICAL RESEARCH AND TECHNOLOGY DEVELOPMENT


KNOXVILLE, TENN., NOV. 30, 1999 -- Photogen Technologies Inc. (NASDAQ: PHGN), developers of non-invasive and minimally invasive diagnostics and therapies, today announced the appointment of David D. Shaw, Ph.D., as the Company's vice president of clinical research and technology development.


At Photogen, Dr. Shaw will be responsible for directing clinical trial programs leading to Food and Drug Administration (FDA) approval of the Company's advanced device and drug technologies. Dr. Shaw's initial efforts will be focused on clinical trials related to the recently announced joint venture with Elan Corporation, plc. The joint venture involves sentinel lymph node mapping, a technique used to determine the degree that a tumor, related to breast, prostate or lung cancer, has spread. The clinical development group will be located in Boston, where Dr. Gerald Wolf, Photogen's medical director, is located.


"With more than 20 years' experience in drug development, specifically in diagnostic imaging and oncology, Dr. Shaw brings a tremendous amount of experience and expertise to our clinical development group," said John Smolik, Photogen president and CEO. "With his strong qualifications, we feel confident that commercialization of our minimally invasive lymphography product will proceed in a professional, timely manner."


"I look forward to being a part of the Company's innovative clinical development group," said Dr. Shaw. "I believe the technologies Photo ...